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Circulating tumor cells (CTCs) are important targets for cancer
biology studies. To further elucidate the role of CTCs in cancer
metastasis and prognosis, effective methods for isolating extremely
rare tumor cells from peripheral blood must be developed. Acoustic-
based methods, which are known to preserve the integrity, func-
tionality, and viability of biological cells using label-free and contact-
free sorting, have thus far not been successfully developed to isolate
rare CTCs using clinical samples from cancer patients owing to
technical constraints, insufficient throughput, and lack of long-term
device stability. In this work, we demonstrate the development of an
acoustic-based microfluidic device that is capable of high-throughput
separation of CTCs from peripheral blood samples obtained from
cancer patients. Our method uses tilted-angle standing surface
acoustic waves. Parametric numerical simulations were performed
to design optimum device geometry, tilt angle, and cell throughput
that is more than 20 times higher than previously possible for such
devices. We first validated the capability of this device by success-
fully separating low concentrations (∼100 cells/mL) of a variety of
cancer cells from cell culture lines from WBCs with a recovery rate
better than 83%. We then demonstrated the isolation of CTCs in
blood samples obtained from patients with breast cancer. Our acous-
tic-based separation method thus offers the potential to serve as an
invaluable supplemental tool in cancer research, diagnostics, drug
efficacy assessment, and therapeutics owing to its excellent biocom-
patibility, simple design, and label-free automated operation while
offering the capability to isolate rare CTCs in a viable state.
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Circulating tumor cells (CTCs) serve as a liquid biopsy targetfor cancer diagnosis, genotyping, and prognosis (1). Moni-
toring the phenotypic and genotypic changes in CTCs during the
course of chemotherapy treatment may be beneficial for guiding
therapeutic decisions (2). In addition, they could provide new
insights into the mostly elusive, yet deadly, process of cancer
metastasis (3–5). To realize these potential benefits from CTCs,
a better understanding of CTCs is needed. However, CTCs are
difficult targets to probe owing to their extremely low concen-
tration in peripheral blood (usually in the range of 1‒100 cells/mL
of blood). Therefore, effective cell separation methods are required
to facilitate the study of CTCs.
Currently, CTC separation methods can be divided into two
major categories: antibody-dependent or antibody-independent
(4). Antibody-dependent methods use tumor-specific antibodies
to identify CTCs. In this approach, in combination with magnetic
or fluorescence markers, CTCs can be isolated from other blood
cells (5, 6). The limitation of this strategy is that the separation of
CTCs requires a priori knowledge of relevant antibodies. How-
ever, the expression of certain biomarkers is a highly dynamic
and heterogeneous process that is specific to the patient. Thus,
results obtained from antibody-dependent methods and the ef-
ficacy of these methods in detecting CTCs could be biased by the
selection of the target antibodies.
As a complementary strategy, antibody-independent methods
allow the separation of CTCs based on their physical properties,
such as size, deformability, and electrical properties without the
need to choose a priori the correct antibodies (7). Among the
various separation methods that rely on cell physical properties
(8–11), approaches predicated on acoustics offer several unique
characteristics (12).
First, acoustic-based separation is known to offer excellent
biocompatibility in terms of preserving the phenotype and geno-
type of the cell compared with other methods. Ultrasound, an
acoustic method widely used in medical imaging for decades, has
been proven to be extremely safe. Recent studies (13) also indicate
that acoustic-based cell separation, which operates at a power in-
tensity and frequency similar to ultrasonic imaging, has little im-
pact on the viability, function, and gene expression of cells, under
appropriate power intensities. Moreover, acoustic separation ap-
proaches do not require modification of the media in which cells
are cultured and separated, and the cells do not require labeling
or surface modification. This biocompatible separation process
maximizes the potential of CTCs to be maintained at their native
states, cultured, and analyzed in vitro or ex vivo. As a result, a large
number of patient-derived cancer cells could be obtained through
venipuncture instead of an invasive biopsy. These characteristics of
the acoustic method enable not only a more accurate, compre-
hensive analysis of CTCs but also offer the potential for better
cancer treatment options, such as noninvasive testing of drug
susceptibility of cancer patients over the course of chemotherapy
(3), and possible early detection of cancer and/or metastasis.
Second, acoustic-based cell separation is the only active
separation method that can differentiate cells based on their
size, density, compressibility, or a combination thereof. Using an
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external acoustic radiation force, separation performance can be
dynamically adjusted to accommodate the separation of different
cell samples with distinct physical differences. In addition to size-
based separation, acoustic-based separation also has the poten-
tial to differentiate cancer cells from normal cells based on their
mechanical properties (13).
Although acoustic-based separation has been demonstrated
for the successful separation of cultured cancer cells from WBCs
(13, 14), it has not been applied so far to the separation of rare
CTCs from clinical samples. This is mainly due to insufficient cell
throughput and long-term operational instability in these devices.
In this work, we report an optimized acoustic separation testing
platform that is capable of enhancing separation throughput of
cancer cells by up to 20 times compared with that previously
achieved using tilted-angle standing surface acoustic waves (taS-
SAWs) while, at the same time, improving separation efficacy. We
also apply the method to study blood samples obtained from
cancer patients. Our device is built upon our recently developed
taSSAW separation strategy (13). We performed systematic
parametric studies of key factors influencing the performance of
the testing platform and determined how these parameters affect
the separation results. After optimizing the design parameters,
such as the tilt angle and the length of the interdigitated trans-
ducers (IDTs) as well as the device power, we tested and validated
the performance of the device by testing cultured cell lines for
different types of cancer. As a result, the separation of rare cancer
cells from WBCs was achieved with higher efficiency than pre-
viously possible. Finally, we applied our taSSAW device for high-
throughput separation of clinical samples and successfully iden-
tified CTCs from breast cancer patients in all cases studied here.
Results
Working Principles and Optimization for High-Throughput Cell
Separation. The taSSAW-based cell separation relies on the es-
tablishment of a standing acoustic wave field inside a fluidic
microchannel. Particles present in such a flow channel will ex-
perience a primary acoustic radiation force:
Fa =−

πp20Vpβw
2λ

φðβ, ρÞsinð2kyÞ, [1]
where p0 and Vp are the acoustic pressure and the volume of the
particle, respectively; λ and k are the wavelength and the wave
number of the acoustic waves, respectively; and φ is the acoustic
contrast factor, which is dependent on the compressibility (β)
and density (ρ) of the particle and the liquid medium. The pri-
mary acoustic radiation force directs cells to either the pressure
nodes or pressure antinodes depending on the sign of the acous-
tic contrast factor (φ). Mammalian cells in a PBS buffer or blood
serum are pushed toward the pressure nodes. From Eq. 1, it is
seen that cells with different physical properties (i.e., size, den-
sity, and compressibility) experience different amplitudes of the
primary acoustic radiation force, which enables the separation of
these cells using acoustic waves.
Fig. 1A illustrates the process of cell separation in a taSSAW
microfluidic device. As shown in Fig. 1B, a series of pressure
nodes and pressure antinodes are established in a microfluidic
channel at an angle tilted to the fluid flow direction. As a result,
cells flowing through the microfluidic channels will pass multiple
regions that have a pair of pressure nodes and antinodes. In each
region, cells will experience different acoustic radiation forces
(Fa) resulting in slightly different movement trajectories. By
passing the cells through such regions repeatedly, the trajectory
differences are further amplified, resulting in separation dis-
tances that can be from a few times to tens of times the acoustic
wavelength, depending on the geometry of the channel. Thus,
the taSSAW separation method (Fig. 1C) is able to overcome the
limitation of conventional acoustic-based separation techniques,
in which the total separation distance is limited to a quarter of
the wavelength of the acoustic waves (15).
As demonstrated in our recent work (13), it is possible to use the
taSSAWmethod to separate a cultured cancer cell line fromWBCs
under a relatively low sample flow rate of 1‒2 μL/min. However,
with this limited throughput, the previous taSSAW separation de-
vice could not be used to separate CTCs. Owing to the rareness of
CTCs in a peripheral blood sample, it is necessary to process a large
number of cells to detect the presence of tumor cells. Thus, high-
throughput separation is a critical requirement for any separation
method targeting clinical CTC applications. To apply taSSAW to
the separation of CTCs, the throughput had to be improved sig-
nificantly. In this regard we first performed a parametric study to
determine the optimized design parameters such as the tilt angle
and length of the IDTs, for high-throughput cell separation.
To find out the practical separation parameters for high-
throughput cell separation, we first established a simulation
model that can numerically describe particle trajectories in the
taSSAW microfluidic device. The model considered the effects of
the acoustic radiation force, the hydrodynamic drag force, and
the laminar flow profile in the microchannel on separation per-
formance. A detailed description of the simulation model can be
found in SI Text, Simulation Model of taSSAW-Based Separation.
After calibrating the simulation model with 10-μm-diameter
polystyrene (PS) beads (SI Text and Fig. S1), we first studied the
dependence of separation distance on tilt angles under different
flow rates. MCF-7 breast cancer cells and WBCs were used as
the separation targets. The physical properties of these cells can
be found in Table S1. The power input was set to 35 dBm. As
shown in Fig. 2A, an optimum tilt angle for maximizing the
separation distance can be found at each flow rate. The simu-
lation results also indicate that as the flow rate increases, the tilt
angle that achieves the highest separation distance decreases.
The reason for this result may be attributed to the fact that
smaller tilted angles allow longer traveling times between pres-
sure antinodes and pressure nodes where the separation occurs.
At high flow rates, the acoustic radiation force cannot dominate
Fig. 1. Schematic illustration and image of the high-throughput taSSAW de-
vice for cancer cell separation. (A) Illustration of taSSAW-based cell separation.
(B) Schematic of the working mechanism behind taSSAW-based cell separation.
The direction of the pressure nodes and pressure antinodes were established at
an angle of inclination (θ) to the fluid flow direction inside a microfluidic
channel. Larger CTCs experience a larger acoustic radiation force (Fac) than
WBCs (Faw). As a result, CTCs have a larger vertical displacement (normal to the
flow direction) than WBCs. Fdc and Fdw are the drag force experienced by CTCs
and WBCs, respectively. (C) An actual image of the taSSAW cell separation
device. Blue ink was used to help visualize the microfluidic channel.
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over the drag force. In this situation, a longer separation time
enabled by the smaller tilt angle will be more advantageous for
cell separation. At lower flow rates, the separation distance be-
tween cells is no longer limited by their exposure time in the
taSSAW because the acoustic radiation force is dominant over
the drag force. In this case, larger tilt angles would increase the
separation distance. For the same flow rate, the simulation in-
dicated that the optimum separation angle increased as the
power increased (Fig. S2). This is because at higher power the
acoustic radiation force becomes more dominant. However, in
practical situations, the applied power input cannot be too high
because it could generate a level of Joule heating that could
damage biological cells and/or device substrates.
Based on this parametric study, we identified the optimum tilt
angle to achieve high-throughput cell separation. Under a prac-
tical power input (35 dBm), the separation distance for MCF-7
cells and WBCs at a 75 μL/min flow rate can reach ∼600 μmwith a
tilt angle of ∼5°, which is sufficient for successful separation at this
throughput (Fig. 2A). When the gross flow rate is 75 μL/min, the
sample flow rate can reach as high as 20 μL/min based on a 2.5:1
sheath-to-sample flow rate ratio, which means 1 mL of WBCs can
be processed within 1 h using this design. Although higher total
flow rates are also possible at even small tilt angles, the separation
distance could be compromised, which is not desirable. It is im-
portant to keep the separation distance as large as possible to
compensate for potential variations in experimental conditions.
After optimizing the flow rate, power input, and tilt angle, the
remaining design parameter that needs to be optimized is the
length of the IDTs (i.e., the length over which the SSAW is ap-
plied). As discussed above, the travel time of the cells across the
taSSAW field, which is dependent on the length of IDTs, is critical
to the cell-separation outcome. Therefore, the length of the IDTs
would inevitably have an impact on the efficiency of cell separa-
tion. In general, the longer the time that it takes the cells to tra-
verse the taSSAW field, the longer is the separation distance.
However, the larger IDTs imply a lower energy density for the
same power input, thereby decreasing the primary acoustic radi-
ation force. There should thus be an optimum IDT length that can
balance these two competing factors. To find the theoretical op-
timum IDT length, we used our simulation to study the relation-
ship between the separation distance and the length of the IDTs at
a fixed flow rate and power input. Fig. 2B shows that the sepa-
ration distance reaches a maximum at around an IDT length of
8‒10 mm. The decrease in the separation distance for shorter and
longer IDTs lengths is caused by insufficient travel time through
the taSSAW field and a lower energy density, respectively.
Demonstration of High-Throughput Separation of Cultured Cancer
Cells from WBCs. We performed experimental verification of the
high-throughput separation of cancer cells from WBCs based on
the optimized values obtained from our simulation. We fabri-
cated IDTs with a tilt angle of 5° and 10-mm length on a lithium
niobate (LiNbO3) piezoelectric substrate. A polydimethylsiloxane
(PDMS) microfluidic channel with height and width of 110 μm
and 800 μm, respectively, was bonded onto the substrate to form
the separation device. For this, the input power is an important
operating parameter. Higher input powers improve the recovery
rate of cancer cells while reducing the removal rate of WBCs,
leading to decreased separation purity. Therefore, it is necessary
to obtain a profile of separation performance at different input
powers. To evaluate the impact of varying the input power, the
separation of MCF-7 and HeLa cells from WBCs was used as a
model. To facilitate the characterization of device performance,
we used an abundant number of cancer cells mixed with WBCs.
Fig. 3 A and B show the relationship between power inputs
and cell-separation performance (the recovery rate and the re-
moval rate of WBCs) for MCF-7 cells and for HeLa cells, re-
spectively. Both MCF-7 cells and HeLa cells showed similar
trends for power input dependence on separation performance.
At lower input powers, the WBC removal rate could be main-
tained at ∼99%, but the recovery rate for cancer cells was only
60‒80%. Using a higher power input can result in greater than
90% cancer cell recovery and ∼90% removal rate of WBCs. In
particular, certain WBCs (e.g., monocytes) that have a larger size
are more easily pushed by the acoustic field, resulting in a de-
crease in the WBC removal rate. The choice of the appropriate
power input for cell separation thus depends on the outcome
desired from optimization. If high sample purity is desired, a
lower power input is preferred to ensure the highest removal rate
of background cells. For CTC applications, the recovery rate of
cancer cells is often more critical because of the inherent rarity
of CTCs. For the following rare-cell separation experiments, we
used the higher input power values (∼37.5 dBm) to ensure a high
recovery rate while maintaining ∼90% removal rate of WBCs.
Fig. 4 shows cell separation in the taSSAWmicrofluidic device.
Before applying the acoustic field, all of the cells flowed toward
the waste outlet. Once the acoustic field was turned on, a clear
separation between cancer cells and WBCs was visible. Cancer
cells were directed toward the collection outlet, whereas a ma-
jority of WBCs still remained in the waste outlet (Movie S1). In
summary, we experimentally demonstrated that the optimized
taSSAW design is capable of separating cancer cells from WBCs
with a flow rate of 1.2 mL/h, which allows us to study the sepa-
ration performance of our device under rare-cell conditions.
Rare-Cell Separation with Multiple Cancer Cell Lines. After verifying
that the device is capable of separating cancer cells from WBCs
with a sample throughput of 1.2 mL/h, we investigated the recovery
of rare cancer cells in a mixture of WBCs. We first examined the
Fig. 2. Theoretical investigation of multiple design parameters for high-
throughput separation using a taSSAW. (A) The relationship between tilt
angle and separation distance under different flow rates. For higher flow
rates, the optimum tilt angle becomes smaller. When flow rates are larger
than 75 μL/min, the separation distance becomes smaller even at the opti-
mum tilt angle. The power input is fixed at 35 dBm. (B) The relationship
between the length of IDTs and the separation distance under a fixed power
input (35 dBm) and flow rate (75 μL/min).
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separation performance of rare MCF-7 cells and also HeLa cells,
because we used them to characterize the device performance, in a
manner similar to that outlined in the previous section. The rare-
cell population was simulated by spiking 50‒1,000 calcein-AM–
stained cancer cells into a 1-mL solution of WBCs. The concen-
tration of WBCs is obtained by directly lysing 1 mL of human whole
blood and resuspending the cells into 1 mL solution of PBS. The
concentration ranges from 3‒6 × 106 cells/mL. The cells were
loaded into the taSSAW device at a flow rate of 1.2 mL/h for high-
throughput separation. The power input was set at 37‒38 dBm, and
the input frequency was 19.573 MHz. Cells, from both the collec-
tion and waste outlets, were collected into two different Petri dishes
with depth and height of 35 mm and 10 mm, respectively. The
number of fluorescent cells in both collection and waste outlets was
counted, and the recovery rate was obtained by dividing the number
of cells in the collection channel by the number of total cells from
both outlets. Typical images for both collection and waste outlets
are shown in Fig. S3. The cell-counting results are summarized in
Table 1. An average recovery rate greater than 87% was obtained
for both the MCF-7 breast cancer cells and the HeLa cells.
After successfully demonstrating rare-cell separation with
MCF-7 and HeLa cells, we also tested the high-throughput
taSSAW device with other cancer cell lines. Because the physical
properties of cells from real cancer patients are unknown a
priori, it is important to test the tolerance of the device with
different cell lines. For this purpose, we used melanoma and
prostate cancer cell models, UACC903M-GFP cells and LNCaP
cells, respectively. Unlike the previous separation for MCF-7 and
HeLa cells in which we first optimized the separation parameters
using abundant cell samples, we directly tested rare-cell con-
centrations of UACC903M-GFP cells and LNCaP cells using the
same operating parameters to separate the MCF-7 and the HeLa
cells. As shown in Table 1, a recovery rate greater than 83% for
these cell lines was also obtained, indicating the robustness of the
device for separating different cancer cell lines.
Study of Cell Viability and Proliferation After Acoustic Separation.As
discussed above, the operating conditions of our taSSAW devices
are conducive to preserving cell integrity during the cell separa-
tion process. To investigate the impact of current separation
conditions on cell integrity, we examined both short-term viability
and long-term cell proliferation following acoustic separation.
We first examined the short-term cell viability after taSSAW
separation using a calcein-AM/propidium iodide (PI) staining
method. One hundred microliters of HeLa cell solution (∼1 ×
106 cells/mL) was passed through the taSSAW separation device
at a flow rate of 20 μL/min. The device-operating parameters
were the same as those used in the aforementioned rare-cell-
separation experiments. After running all of the samples through
the device, cells from the collection outlet were stained with
calcein-AM/PI for 15 min at room temperature to determine
their viability. Cells with a calcein-AM+/PI− staining pattern
were counted as live cells, whereas cells with calcein-AM−/PI+
and calcein-AM+/PI+ staining patterns were counted as dead
cells. As shown in Fig. 5A, the cell viability of HeLa cells for the
Fig. 3. The cancer cell separation performance under different power in-
puts at a 20 μL/min flow rate. (A) The relationship between power input and
separation performance for separation of MCF-7 from WBCs. (B) The re-
lationship between power input and separation performance for separation
of HeLa from WBCs. Both cancer cell lines showed a similar relationship
between the power input and separation performance. Higher power input
would result in better cancer cell recovery rates and lower WBCs removal
rates, and vice versa. Error bars represent the relative counting error. The
number of cells (n) passing through collection channel and waste channel
were counted, respectively. n > 100 for cancer cells, and n > 350 for WBCs.
Fig. 4. Micrographs of the separation process with
acoustic field ON and OFF. (A) The mixture of HeLa
cells and WBCs through a microfluidic channel
with the acoustic field OFF. All of the cells were di-
rected to the lower waste outlet by the hydrody-
namic flow. No separation is observed. (B) When the
acoustic field is ON, larger HeLa cells were pushed to
the collection outlet, whereas the smaller WBCs still
remained in the waste outlet. The separation be-
tween HeLa cells and WBCs can be observed. The
stacked images are from 50 consecutive frames.
(Scale bars, 515 μm.) (C and D) Zoomed-in images
of the collection outlet and the waste outlet, re-
spectively. (Scale bars, 30 μm.)
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acoustic ON and OFF groups were determined to be 90.4 ±
4.7% and 91.5 ± 7.6%, respectively. The results indicated no
significant change in cell viability after applying the taSSAW.
Representative fluorescence images are shown in Fig. 5 B and C.
After determining short-term cell viability, it is also important to
examine whether cells continue to proliferate normally after the
separation process. To simulate the actual CTC separation con-
ditions, 100 HeLa cells were spiked into 1 mL of PBS solution and
passed through the acoustic device. The flow rate and acoustic
power input were the same as previous rare-cell separation ex-
periments. The separated HeLa cells were collected into a
35- ×10-mm Petri dish with 1 mL of DMEM/F12 cell culture me-
dium. After collecting cells for about 1 h, the cell-collection Petri
dish was transferred to an incubator. Cells were then cultured
overnight at 37 °C and under 5% CO2. After culturing for 12 h, the
50% diluted DMEM/F12 cell culture medium (vol/vol, PBS/me-
dium) was changed to the original undiluted medium. Fig. 5D shows
images of the cultured HeLa cells focused at the same location over
a long time period (1 wk). Normally, HeLa cells divide once every
20 h. From the images, we see that the cells have maintained their
normal proliferation rates after running through the taSSAW sep-
aration conditions. Collectively, these short-term and long-term cell
viability and proliferation experiments demonstrated that our high-
throughput taSSAW separation approach is biocompatible and can
maintain long-term, normal cell physiological processes.
Probing CTCs from Breast Cancer Patient Blood Samples.As a practical
demonstration, we tested our taSSAW device with blood samples
obtained from three patients with metastatic breast cancer. Im-
munofluorescent staining of cytokeratin (CK) and pan-leukocyte
marker CD45 was used to first determine the identity of the cells
using conventional detection methods. Cells were identified as
CTCs if the immunofluorescent pattern is DAPI+/CK8,18+/CD45−;
otherwise, cells were identified as WBCs. Based on this im-
munostaining detection criteria and using the taSSAW devices, 59
and 8 CTCs were found in the first two patients, respectively, in
2-mL blood samples from each patient. Both of these patients had
CTCs detected by the Veridex assay on previous occasions. The
third patient had only one CTC after screening 6 mL of blood.
Typical fluorescent images are shown in Fig. 6. WBCs can be
distinguished from the CTCs because they showed an immunos-
taining pattern of DAPI+/CK8,18−/CD45+. Using immunofluo-
rescence, we could also check the expression of certain protein
markers in patients’ CTCs after our taSSAW-based separation. In
this case, we examined the expression of estrogen receptor (ER) in
the patients’ CTCs. As shown in Fig. 6A, the MCF-7 cell line was
used as a positive control for ER. Compared with the fluorescent
signal from the ER in the MCF-7 cells, all of the patient samples
were considered negative for ER. All three patients had initial
diagnosis of ER+ breast cancer. The first two patients (with CTC
counts of 59 and 8, respectively) had been heavily pretreated with
multiple lines of endocrine therapy as well as chemotherapy and
had chemotherapy refractory disease. In the first patient immu-
nohistochemical staining of a biopsy of a metastatic site (bone)
showed persistent ER positivity and progesterone receptor (PR)
positivity at 5%; the second patient had biopsy of her metastatic
tumor in the pelvis and this was ER-positive at 100% and PR-
positive at 1%. Loss of ER positivity in the CTCs from patients
with initial diagnosis of ER positive breast cancer has been pre-
viously reported and could be a reflection of tumor heterogeneity
(16). The third patient had a low (1) CTC count, which is consis-
tent with the fact that the blood was drawn within 2 mo after ini-
tiating a new line of endocrine therapy to which she responded; this
was ascertained by clinical examination and imaging (CT scans).
Discussion
In this work, we demonstrated taSSAW-based high-throughput
cell separation by systematically investigating the effects of
multiple design parameters on the separation performance. We
showed that under different flow rates the optimum tilt angle
would be different. In general, higher flow rates would require
smaller optimum tilt angles. After systematic optimization, we
demonstrated that the taSSAW device was capable of separating
cancer cells from WBCs under a flow rate of 20 μL/min. This
result facilitated the practical use of this device to isolate rare
cells from spiked blood samples. We further demonstrated that
this high-throughput cell separation method works with real
clinical samples by successfully isolating CTCs in the blood
samples from three breast cancer patients. The acoustic-based
separation method demonstrated here features several advantages
for CTC separation applications such as high biocompatibility,
automated operation, and label-free, contactless nature, all in a
simple, inexpensive and compact device.
The taSSAW-based separation involves multiple parameters
that may affect the cell-separation performance, such as the flow
Table 1. Rare-cell separation with multiple-spiked cancer cell lines
Cell line
Cells ratio (cancer
cells/WBCs)
No. of cancer cells
(collection outlet)
No. of cancer cells
(waste outlet) Recovery rate, %
MCF-7 1:40,000 121 20 86
MCF-7 1:40,000 90 11 89
MCF-7 1:40,000 52 2 96
HeLa 1:6,000 907 165 85
HeLa 1:100,000 49 10 83
HeLa 1:40,000 131 7 95
UACC903M-GFP 1:100,000 64 12 84
UACC903M-GFP 1:100,000 36 7 84
UACC903M-GFP 1:100,000 28 5 85
LNCaP 1:20,000 111 12 90
Fig. 5. Short-term viability test and long-term culture of HeLa cells after taS-
SAW separation. (A) Cell viability comparison between the acoustic ON group
and acoustic OFF group using calcein-AM/PI staining method. No significant
difference was found between the “Acoustic ON” group and control group.
(B and C) Representative images of live/dead cell staining for the “Acoustic ON”
group and the control group, respectively. Calcein-AM, PI, and bright-field
channels were overlaid and pseudo colors were assigned to calcein-AM (green)
and PI (red) channels. Red color indicates dead cells. (Scale bars, 100 μm.)
(D) Long-term culture of rare HeLa cells after acoustic separation. (Scale bar, 35 μm.)
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rate, input power, tilt angle, and the length of the IDTs, in ad-
dition to cell physical properties. All these parameters have in-
terdependent and complex relationships. Therefore, it would
require a large combination of experimental trials to determine
the optimized values. In this work, we have shown that a
straightforward simulation model that carefully considered the
acoustic radiation force, the hydrodynamic drag force, channel
flow with a laminar velocity profile, and cell physical properties
could effectively guide the optimization of the taSSAW device
for high-throughput cell separation. The simulation model can
be further improved if the physical properties of clinical CTC
samples were readily available. However, the current physical
properties of clinical CTCs, specifically compressibility, are still
largely undocumented and unknown. In future studies, it will be
ideal to establish the physical and mechanical property profiles
of CTCs from different cancer populations (17). By establishing
a statistical database of the physical properties of CTCs from
patient samples, the current simulation model can be further
refined, thereby leading to more optimized taSSAW designs for
clinical CTC samples. Conversely, it could also enable probing
the mechanical properties of CTCs via acoustic methods.
In our previous publication (13), we demonstrated that the
taSSAW method could effectively separate particles with small
difference in physical properties such as size, density, and
compressibility. For example, we separated 9.9-μm PS beads from
7.3-μm ones, with an efficiency of 97% or higher. In this work, we
demonstrated the effective separation of rare cancer cells (with
average diameters of 16 or 20 μm depending on the cancer cell lines
used) from WBCs (diameter ∼12 μm). Cancer cell recovery rate is
>83% (83–96%) and WBC removal rate is ∼90%. The method is
expected to work very well for cancer cells that have significant size
(or density/compressibility) differences with respect to WBCs. For
cancer cells that have similar physical properties compared with
WBCs, the method could be less effective and optimized specific
device design would be even more critical in that case.
In this work, RBCs were removed using an RBC lysis buffer to
facilitate the separation process. The use of an RBC lysis buffer
has also been used by other CTC separation methods and has
shown no negative impact on cancer cells (8). However, the RBC
lysis step added extra sample processing time and decreased the
overall processing throughput. In future studies, it would be
desirable to integrate an RBC-removal function into the same
microfluidic chip. For instance, continuous-flow RBC removal
methods predicated upon deterministic later displacement could
be integrated with the taSSAW-based separation device to en-
able processing of whole blood (18).
Although this work focuses on developing taSSAW for high-
throughput separation of CTCs, this approach is not limited to
CTC applications. Virtually all separation applications will ben-
efit from an increase in throughput. Acoustic-based separation
has been demonstrated in many applications where the physical
properties of target cells are different from those of the back-
ground cells (19, 20). Therefore, the high-throughput taSSAW
approach developed here could also improve separation perfor-
mance in other applications, such as cell washing, cell synchro-
nization, blood component separations, and bacteria separation.
Materials and Methods
Device Fabrication and Experimental Setup. Details of the device fabrication
process flow can be found in our previous work (13). Details of the experi-
mental setups and procedures can be found in SI Text, Experimental Setup
and Procedures.
Cell Culture and Sample Preparation. Standard cell culture and handling
procedures were followed. Detailed procedures can be found in SI Text, Cell
Cultures and Sample Preparation.
Patient Blood Processing and Image Acquisition. Informed consent was ob-
tained for clinical samples used on a clinical protocol approved by The
Pennsylvania State University Institutional Review Board. Detailed procedures of
blood processing, immunofluorescence staining, and image acquisition can be
found in SI Text, Patients’ Blood Processing, Immunofluorescence Staining, and
Image Acquisition.
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Fig. 6. Immunofluorescence images for the identification of CTCs in blood
samples from breast cancer patients. Four channels, DAPI, CK8,18, CD45, and
ER, were examined. The MCF-7 cell was used as the positive control, showing
a staining pattern of DAPI+/CK8,18+/CD45−/ER+. CTCs were identified as
they showed a staining pattern DAPI+/CK8,18+/CD45−. In contrast, WBCs
showed a staining pattern DAPI+/CK8,18−/CD45+. (Scale bar, 4 μm.)
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